SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product name KADCYLA™ Solution
Product code CSE-3090
Synonyms - T-DM1 (RO5304020) 2% aqueous solution with excipients

1.2. Relevant identified uses of the substance or mixture and uses advised against

Use - formulated pharmaceutical active substance (antineoplastic)

1.3. Details of the supplier of the safety data sheet

Company information
Hoffmann-La Roche Inc.
340 Kingsland Street
USA-Nutley, N.J. 07110-1199
United States of America

Enquiries:
Phone 001-973/235 50 00
E-Mail info.sds@roche.com

US Emergency phone: (800)-827-6243
US Chemtrec phone: (800)-424-9300

Local representation:

1.4. Emergency telephone number

Emergency telephone number
US emergency phone: (800)-827-6243

SECTION 2: Hazards identification

Emergency Overview

Form liquid
Color colorless
Hazard Overview - May cause allergic reactions.
- Harmful if swallowed.
- May cause birth defects based on information on related materials
KADCYLA™ Solution

Potential Health Effects
- Exposure: Inhalation, Ingestion, Skin contact, Eye contact
- Target Organs: liver, Cardiovascular system, gastrointestinal system, Hematopoietic/blood system, Immune System, respiratory system

- Acute Effects: May cause allergic reactions., Harmful if swallowed., May cause headache., May cause musculoskeletal effects., May cause general body weakness, fatigue and nausea.

- Chronic Effects: May cause hepatic (liver) system effects., Signs and symptoms may include elevation of liver enzyme levels and jaundice (yellowing of the skin and eyes)., May cause cardiovascular effects., Signs and symptoms may include increase or decrease in blood pressure, irregular heartbeat, chest pains and cardiac arrest., May cause blood system changes., May cause respiratory effects., Signs and symptoms may include difficulty in breathing, coughing, wheezing, irritation (inflammation) and respiratory arrest.

- Carcinogenicity: not listed by NTP, IARC or OSHA

Classification of the substance or mixture / Label elements

GHS Classification
Health Hazards:
3.1 oral Acute toxicity (Category 4)
H302 Harmful if swallowed.

Signalword: Warning
Label:

Precautionary statements:
- P312 Call a POISON CENTER or doctor/physician if you feel unwell.

Other hazards

Additional Health Information
- Conditions Aggravated: Hypersensitivity to this material and other materials in its chemical class.
- Reproduction Toxicity: May cause birth defects. Since this material may affect the developing fetus, females planning to have a child and pregnant women should exercise caution regarding exposure.
- It is also advisable for nursing mothers to exercise caution regarding exposure.

SECTION 3: Composition/information on ingredients

Characterization
antibody-drug conjugate consisting of the antibody trastuzumab (the active ingredient in Herceptin) linked to a cytotoxic agent that is a derivative of maytansine (DM1)
KADCYLA™ Solution

### Ingredients

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>ado-trastuzumab emtansine</td>
<td>~ 2 %</td>
</tr>
<tr>
<td>CAS: 1018448-65-1</td>
<td></td>
</tr>
</tbody>
</table>

### SECTION 4: First aid measures

#### 4.1. Description of first aid measures

- **Eye contact**: Rinse immediately with tap water for 10 minutes - open eyelids forcibly
- **Skin contact**: Remove immediately contaminated clothes, wash affected skin with water and soap - do not use any solvents
- **Inhalation**: Remove the casualty to fresh air and keep him/her calm - in the event of symptoms get medical treatment

#### 4.2. Most important symptoms and effects, both acute and delayed

- **Note**: No information available

#### 4.3. Indication of any immediate medical attention and special treatment needed

- **Note to physician**: Treat symptomatically

### SECTION 5: Firefighting measures

#### 5.1. Extinguishing media

- **Suitable extinguishing media**: Adapt extinguishing media to surrounding fire conditions, water spray jet, dry powder, foam, carbon dioxide
- **Flash point (liquid)**: Not applicable

#### 5.2. Special hazards arising from the substance or mixture

- **Specific hazards**: Does not present a fire hazard

#### 5.3. Advice for firefighters

- **Protection of fire-fighters**: Precipitate gases/vapours/mists with water spray

### SECTION 6: Accidental release measures

#### 6.1. Personal precautions, protective equipment and emergency procedures

- **Personal precautions**: Avoid exposure
KADCYLA™ Solution

6.2. Environmental precautions

Environmental protection - if the substance reaches waters or the sewer system, inform the competent authority

6.3. Methods and material for containment and cleaning up

Methods for cleaning up - wash contaminated surfaces with sodium hydroxide solution, c(NaOH)=0.5 mol/l to 1 mol/l, and rinse with water

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Technical measures - avoid formation of aerosols

7.2. Conditions for safe storage, including any incompatibilities

Storage conditions - below -20°C

Validity - 24 hours, 25 °C

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Threshold value (Roche) air - IOEL (Internal Occupational Exposure Limit): 0.0003 mg/m³ *1

8.2. Exposure controls

General protective and hygiene measures - instruction of employees recommended

Hand protection - protective gloves

Eye protection - safety glasses

*1 referring to: ado-trastuzumab emtansine

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Color - colorless

Form - liquid
KADCYLA™ Solution

9.2. Other information
Note - no information available

SECTION 10: Stability and reactivity

10.1. Reactivity
Note - no information available

10.2. Chemical stability
Stability - do not dilute with glucose since there cause aggregation of the protein *2

10.3. Possibility of hazardous reactions
Note - no information available

10.4. Conditions to avoid
Conditions to avoid - light - warming

10.5. Incompatible materials
Note - no information available

10.6. Hazardous decomposition products
Note - no information available

*2 referring to: Herceptin Vials (2% Trastuzumab solution with excipients)

SECTION 11: Toxicological information

11.1. Information on toxicological effects

<table>
<thead>
<tr>
<th>Type</th>
<th>Value 1</th>
<th>Value 2</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute toxicity</td>
<td>HNSTD 30 mg/kg (i.v., cynomolgus monkey)</td>
<td>*1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>HNSTD 20 mg/kg (i.v., rat)</td>
<td>*1</td>
<td></td>
</tr>
<tr>
<td>Subacute toxicity</td>
<td>HNSTD 10 mg/kg/week (i.v., cynomolgus monkey, 9 weeks)</td>
<td>*1</td>
<td></td>
</tr>
<tr>
<td>Sensitization</td>
<td>anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described</td>
<td>*3</td>
<td></td>
</tr>
</tbody>
</table>

*1, *2, *3 referring to: --
### KADCYLA™ Solution

<table>
<thead>
<tr>
<th>Note</th>
<th>- HNSTD = Highest Non-Severely Toxic Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>*1</td>
<td>referring to: ado-trastuzumab emtansine</td>
</tr>
<tr>
<td>*3</td>
<td>referring to: Trastuzumab</td>
</tr>
</tbody>
</table>

### SECTION 12: Ecological information

#### 12.1. Toxicity

Ecotoxicity

- barely inhibitory on aerobic bacterial respiration (activated sludge) concentration (14 d) 49.5 mg/l (nominal concentration) (Manometric Respirometry Test, OECD No. 301 F) *4
- barely toxic for algae, growth inhibition possibly due to turbidity caused by test substance (Desmodesmus (=Scenedesmus) subspicatus) ErC_{50} (72 h) > 100 mg/l (nominal concentration) EyC_{50} (72 h) ~ 100 mg/l (nominal concentration) (OECD No. 201) *1
- barely toxic for planktonic crustaceans (Daphnia magna) EC_{50} (48 h) > 100 mg/l (nominal concentration) NOEC (48 h) 100 mg/l (nominal concentration) (OECD No. 202) *1
- barely toxic for fish (guppy) LC_{50} (96 h) > 100 mg/l (nominal concentration) NOEC (96 h) < 100 mg/l (nominal concentration) (OECD No. 203, semistatic) *1

#### 12.2. Persistence and degradability

Ready biodegradability

- readily biodegradable 84 %, 28 d (Manometric Respirometry Test, OECD No. 301 F) *4

#### 12.3. Bioaccumulative potential

Note | - no information available

#### 12.4. Mobility in soil

Note | - no information available

#### 12.5. Results of PBT and vPvB assessment

Note | - no information available

#### 12.6. Other adverse effects

Note | - no information available

| *1   | referring to: ado-trastuzumab emtansine   |
| *4   | referring to: Trastuzumab-MCC-DM1 Lyophilized |
### SECTION 13: Disposal considerations

#### 13.1. Waste treatment methods

| Waste from residues | - observe local/national regulations regarding waste disposal  
|                     | - incinerate in qualified installation with flue gas scrubbing |

### SECTION 14: Transport information

**Note**
- not classified by transport regulations, proper shipping name non-regulated

### SECTION 15: Regulatory information

#### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

<table>
<thead>
<tr>
<th>TSCA Status</th>
<th>- FDA Exemption - not on inventory</th>
</tr>
</thead>
</table>

| Reporting Requirements | - The United States Environmental Protection Agency (USEPA) has not established a Reportable Quantity (RQ) for releases of this material.  
|                        | - In New Jersey, report all releases which are likely to endanger the public health, harm the environment or cause a complaint to the NJDEPE Hotline (1-609-292-5560) and to local officials.  
|                        | - State and local regulations vary and may impose additional reporting requirements. |

### SECTION 16: Other information

| Edition documentation | - first edition |

The information in this safety data sheet is based on current scientific knowledge. It should not be taken as expressing or implying any warranty concerning product characteristics.
SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product name: KADCYLA™ Lyophilized Powder in Vials (100 & 160 mg)
Product code: RO5304020-F02
Synonyms: - T-DM1 with excipients lyophilized
- Kadcyla

1.2. Relevant identified uses of the substance or mixture and uses advised against

Use: - formulated pharmaceutical active substance (antineoplastic)

1.3. Details of the supplier of the safety data sheet

Company information: Enquiries: Hoffmann-La Roche Inc.
Hoffmann-La Roche Inc.
340 Kingsland Street
USA-Nutley, N.J. 07110-1199
United States of America

Local representation:
Phone: 001-973/235 50 00
E-Mail: info.sds@roche.com

US Emergency phone: (800)-827-6243
US Chemtrec phone: (800)-424-9300

1.4. Emergency telephone number

Emergency telephone number: US emergency phone: (800)-827-6243

SECTION 2: Hazards identification

Emergency Overview

Form: lyophilized powder
Color: white
Hazard Overview: - May cause allergic reactions.
- Harmful if swallowed.
- May cause birth defects based on information on related materials
KADCYLA™ Lyophilized Powder in Vials (100 & 160 mg)

Potential Health Effects
- Exposure: Inhalation, Ingestion, Skin contact, Eye contact
- Target Organs: liver, Cardiovascular system, gastrointestinal system, Hematopoietic/blood system, Immune System, respiratory system
- Acute Effects: May cause allergic reactions., Harmful if swallowed., May cause headache., May cause musculoskeletal effects., May cause general body weakness, fatigue and nausea.
- Chronic Effects: May cause hepatic (liver) system effects., Signs and symptoms may include elevation of liver enzyme levels and jaundice (yellowing of the skin and eyes)., May cause cardiovascular effects., Signs and symptoms may include increase or decrease in blood pressure, irregular heartbeat, chest pains and cardiac arrest., May cause blood system changes., May cause respiratory effects., Signs and symptoms may include difficulty in breathing, coughing, wheezing, irritation (inflammation) and respiratory arrest.
- Carcinogenicity: not listed by NTP, IARC or OSHA

Classification of the substance or mixture / Label elements

GHS Classification

Health Hazards:
3.1 dermal Acute toxicity (Category 4)
   H312 Harmful in contact with skin.
3.1 oral Acute toxicity (Category 3)
   H301 Toxic if swallowed.
3.5 Germ cell mutagenicity (Category 1B)
   H340 May cause genetic defects.
3.6 Carcinogenicity (Category 1B)
   H350 May cause cancer.
3.7 FD Reproductive toxicity (Category 1B)
   H360FD May damage fertility. May damage the unborn child.

Signalword: Danger

Label:

Precautionary statements:
- P201 Obtain special instructions before use.
- P280 Wear protective gloves/ protective clothing / eye protection / face protection.
- P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
- P302 + P352 IF ON SKIN: Wash with plenty of soap and water.
- P309 + P310 IF exposed or if you feel unwell: Immediately call a POISON CENTER or doctor/physician.

Other hazards

Additional Health Information
- Conditions Aggravated: Hypersensitivity to this material and other materials in its chemical class.
SECTION 3: Composition/information on ingredients

Characterization
antibody-drug conjugate consisting of the antibody trastuzumab (the active ingredient in Herceptin) linked to a cytotoxic agent that is a derivative of maytansine (DM1)

Ingredients

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>Concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>ado-trastuzumab emtansine</td>
<td>~ 24 %</td>
</tr>
<tr>
<td>CAS: 1018448-65-1</td>
<td></td>
</tr>
</tbody>
</table>

SECTION 4: First aid measures

4.1. Description of first aid measures

Eye contact
- rinse immediately with tap water for 10 minutes - open eyelids forcibly

Skin contact
- remove immediately contaminated clothes, wash affected skin with water and soap - do not use any solvents

Inhalation
- remove the casualty to fresh air and keep him/her calm
- in the event of symptoms get medical treatment

4.2. Most important symptoms and effects, both acute and delayed

Note
- no information available

4.3. Indication of any immediate medical attention and special treatment needed

Note to physician
- treat symptomatically

SECTION 5: Firefighting measures

5.1. Extinguishing media

Suitable extinguishing media
- adapt extinguishing media to surrounding fire conditions, water spray jet, dry powder, foam, carbon dioxide

Flash point (liquid)
not applicable

5.2. Special hazards arising from the substance or mixture

Specific hazards
- consider dust explosion hazard
KADCYLA™ Lyophilized Powder in Vials (100 & 160 mg)

5.3. Advice for firefighters

Protection of fire-fighters - precipitate gases/vapours/mists with water spray

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions - prevent any exposure

6.2. Environmental precautions

Environmental protection - if the substance reaches waters or the sewer system, inform the competent authority

6.3. Methods and material for containment and cleaning up

Methods for cleaning up - collect solids (avoid dust formation) and hand over to waste removal
- wash contaminated surfaces with sodium hydroxide solution, c(NaOH)=0.5 mol/l to 1 mol/l, and rinse with water

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Suitable materials - glass

7.2. Conditions for safe storage, including any incompatibilities

Storage conditions - 2 - 8 °C
- do not freeze
- protected from light

Validity - see expiry date on the label

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Threshold value (Roche) air - IOEL (Internal Occupational Exposure Limit): 0.0003 mg/m³

8.2. Exposure controls

General protective and hygiene measures - instruction of employees mandatory
KADCYLA™ Lyophilized Powder in Vials (100 & 160 mg)

Respiratory protection
- Respiratory protection is recommended as a precaution to minimize exposure. Effective engineering controls are considered to be the primary means to control worker exposure. Respiratory protection should not substitute for feasible engineering controls.
- Respiratory protection is recommended for dusty operations.
- Respiratory protection not necessary during normal operations

Hand protection
- protective gloves

Eye protection
- safety glasses

*1 referring to: ado-trastuzumab emtansine

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Color
white

Form
lyophilized powder

Solubility
soluble, water

9.2. Other information

Note
- no information available

SECTION 10: Stability and reactivity

10.1. Reactivity

Note
- no information available

10.2. Chemical stability

Stability
- do not dilute with glucose since there cause aggregation of the protein

10.3. Possibility of hazardous reactions

Note
- no information available

10.4. Conditions to avoid

Conditions to avoid
- light
- warming
- humidity

10.5. Incompatible materials

Note
- no information available
10.6. Hazardous decomposition products

Note: no information available

*2 referring to: Herceptin Vials (2% Trastuzumab solution with excipients)

SECTION 11: Toxicological information

11.1. Information on toxicological effects

<table>
<thead>
<tr>
<th>Acute toxicity</th>
<th>HNSTD 30 mg/kg (i.v., cynomolgus monkey) *1</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HNSTD 20 mg/kg (i.v., rat) *1</td>
</tr>
<tr>
<td>Subacute toxicity</td>
<td>HNSTD 10 mg/kg/3w (i.v., cynomolgus monkey, 9 weeks) *1</td>
</tr>
<tr>
<td>Sensitization</td>
<td>anaphylactic reactions may occur following the intravenous application of proteins; rare cases of hypersensitivity have been described *3</td>
</tr>
</tbody>
</table>

Note: HNSTD = Highest Non-Severely Toxic Dose

*1 referring to: ado-trastuzumab emtansine

*3 referring to: Trastuzumab

SECTION 12: Ecological information

12.1. Toxicity

Ecotoxicity: barely toxic for algae, growth inhibition possibly due to turbidity caused by test substance (Desmodesmus (=Scenedesmus subspicatus))

ErC50 (72 h) > 100 mg/l (nominal concentration)
EyC50 (72 h) ~ 100 mg/l (nominal concentration) (OECD No. 201)

- barely toxic for planktonic crustaceans (Daphnia magna)
  EC50 (48 h) > 100 mg/l (nominal concentration)
  NOEC (48 h) 100 mg/l (nominal concentration) (OECD No. 202)

- barely toxic for fish (guppy)
  LC50 (96 h) > 100 mg/l (nominal concentration)
  NOEC (96 h) < 100 mg/l (nominal concentration) (OECD No. 203, semistatic)

- barely inhibitory on aerobic bacterial respiration (activated sludge) concentration (14 d) 49.5 mg/l (nominal concentration) (Manometric Respirometry Test, OECD No. 301 F)

12.2. Persistence and degradability

Ready biodegradability: readily biodegradable
84 %, 28 d
(Manometric Respirometry Test, OECD No. 301 F)
12.3. Bioaccumulative potential
Note - no information available

12.4. Mobility in soil
Note - no information available

12.5. Results of PBT and vPvB assessment
Note - no information available

12.6. Other adverse effects
Note - no information available

*1 referring to: ado-trastuzumab emtansine

SECTION 13: Disposal considerations

13.1. Waste treatment methods
Waste from residues - observe local/national regulations regarding waste disposal
- incinerate in qualified installation with flue gas scrubbing

SECTION 14: Transport information

<table>
<thead>
<tr>
<th>IATA</th>
<th>Class</th>
<th>UN/ID</th>
<th>PG</th>
<th>PI</th>
<th>Label</th>
<th>Mark</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1</td>
<td>3249</td>
<td>III</td>
<td></td>
<td>670/677</td>
<td>6.1</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IMDG</th>
<th>Class</th>
<th>UN</th>
<th>PG</th>
<th>EmS</th>
<th>PI</th>
<th>Label</th>
<th>Mark</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1</td>
<td>3249</td>
<td>III</td>
<td>F-A S-A</td>
<td>P002/-</td>
<td>6.1</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RID/ADR</th>
<th>Class</th>
<th>UN</th>
<th>PG</th>
<th>Haz.no</th>
<th>PI</th>
<th>Label</th>
<th>Mark</th>
<th>Classif. code</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1</td>
<td>3249</td>
<td>III</td>
<td>60</td>
<td>P002/-</td>
<td>6.1</td>
<td></td>
<td>T2</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DOT</th>
<th>Class</th>
<th>UN/ID</th>
<th>PG</th>
<th>PI</th>
<th>RQ</th>
<th>Label</th>
<th>Haz.no</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.1</td>
<td>3249</td>
<td>III</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.1</td>
</tr>
</tbody>
</table>
KADCYLA™ Lyophilized Powder in Vials (100 & 160 mg)

Proper shipping name
MEDICINE, SOLID, TOXIC, N.O.S.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

TSCA Status
- FDA Exemption - not on inventory

Reporting Requirements
- The United States Environmental Protection Agency (USEPA) has not established a Reportable Quantity (RQ) for releases of this material.
- In New Jersey, report all releases which are likely to endanger the public health, harm the environment or cause a complaint to the NJDEPE Hotline (1-609-292-5560) and to local officials.
- State and local regulations vary and may impose additional reporting requirements.

SECTION 16: Other information

Note
- This product may be shipped using De Minimis Quantity Exceptions, if the requirements of US 49 CFR §173.4b and ICAO 5.6/IATA 2.6.10 are met.

Edition documentation
- changes from previous version in sections 16

The information in this safety data sheet is based on current scientific knowledge. It should not be taken as expressing or implying any warranty concerning product characteristics.